Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety via a linker reported to be useful for the treatment of cancer.
Ensem Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα mutant inhibitors, reported to be useful for the treatment of cancer.
The U.S. Patent and Trademark Office has reacted to the Federal Circuit’s decision in Shockwave v. CLSI with a policy memo that draws tighter lines around the use of applicant admitted prior art in attempts to invalidate a patent during inter partes reviews.
Technische Universität München has described conjugates comprising a silicone-based fluoride acceptor (SiFA)-based peptide targeting moiety covalently linked to radiolabeled chelating agents through a divalent linker.
Haisco Pharmaceutical Group Co. Ltd. has identified sulfur-containing heterocyclic derivatives acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Novartis AG has synthesized cyanotrizole compounds reported to be useful for the treatment of leishmaniasis, American trypanosomiasis (Chagas disease) and African trypanosomiasis (sleeping sickness).
Pfizer Inc. has disclosed salts of gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be useful for the treatment of type 2 diabetes and obesity.
Ennovathera Inc. has described compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of cancer, transplant rejection, inflammation, and endocrine, autoimmune and neurological disorders.
RSS
